Literature DB >> 31549492

Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.

Arun K Ghosh1, Zilei Xia1, Satish Kovela1, William L Robinson1, Megan E Johnson1, Daniel W Kneller2, Yuan-Fang Wang2, Manabu Aoki3,4, Yuki Takamatsu4, Irene T Weber2, Hiroaki Mitsuya5,3,4.   

Abstract

We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic acid containing inhibitors showed very poor antiviral activity relative to carboxamide-derived inhibitors which showed good antiviral IC50 value. Boronic acid derived inhibitor with bis-THF as the P2 ligand showed very potent enzyme inhibitory activity, but it showed lower antiviral activity than darunavir in the same assay. Boronic acid containing inhibitor with a P2-Crn-THF ligand also showed potent enzyme Ki but significantly decreased antiviral activity. We have evaluated antiviral activity against a panel of highly drug-resistant HIV-1 variants. One of the inhibitors maintained good antiviral activity against HIVDRV R P20 and HIVDRV R P30 viruses. We have determined high resolution X-ray structures of two synthetic inhibitors bound to HIV-1 protease and obtained molecular insight into the ligand-binding site interactions.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  HIV-1 protease inhibitors; brain penetration; drug resistance; genetic barriers; structure-based design

Year:  2019        PMID: 31549492      PMCID: PMC6842059          DOI: 10.1002/cmdc.201900508

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  41 in total

Review 1.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.

Authors:  A Wlodawer; J Vondrasek
Journal:  Annu Rev Biophys Biomol Struct       Date:  1998

2.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

3.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

Authors:  Andrey Y Kovalevsky; Fengling Liu; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2006-08-04       Impact factor: 5.469

4.  Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

Authors:  Chen-Hsiang Shen; Yuan-Fang Wang; Andrey Y Kovalevsky; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2010-08-02       Impact factor: 5.542

5.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

Review 6.  Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.

Authors:  S-F Zhou
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

7.  Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

Authors:  Sandra De Meyer; Erkki Lathouwers; Inge Dierynck; Els De Paepe; Ben Van Baelen; Tony Vangeneugden; Sabrina Spinosa-Guzman; Eric Lefebvre; Gaston Picchio; Marie-Pierre de Béthune
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

Review 8.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

9.  JLigand: a graphical tool for the CCP4 template-restraint library.

Authors:  Andrey A Lebedev; Paul Young; Michail N Isupov; Olga V Moroz; Alexey A Vagin; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2012-03-17

10.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  2 in total

Review 1.  Merging the Versatile Functionalities of Boronic Acid with Peptides.

Authors:  Yahong Tan; Junjie Wu; Lulu Song; Mengmeng Zhang; Christopher John Hipolito; Changsheng Wu; Siyuan Wang; Youming Zhang; Yizhen Yin
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 2.  Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications.

Authors:  Mariana Pereira Silva; Lucília Saraiva; Madalena Pinto; Maria Emília Sousa
Journal:  Molecules       Date:  2020-09-21       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.